[FORM 12b-25 NOTIFICATION OF LATE FILING CUSIP NUMBER: 090678 301 o o o (Check One): x o o For Period Ended: March 31, 2017 o o o o o For the Transition Period Ended: ____________________ Nothing in this form shall be construed to imply that the Commission has verified any information contained herei]
[] [CERTIFICATION OF OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li, certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to m]
[] [CERTIFICATION OF OF THE SARBANES-OXLEY ACT OF 2002 I, Zhilin Li, certify that: 1. I have reviewed this report on Form 10-Q of China Pharma Holdings, Inc.; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to m]
[Schedule 14A ☒ ☐ Check the appropriate box: ☐ ☐ ☒ ☐ ☐ Biostar Pharmaceuticals, Inc. _____________________________________ Payment of Filing Fee (Check the appropriate box): ☒ ☐ (1) Title of each class of securities to which transaction applies: _____________________________ (2) Aggregate number of s]
[Schedule 14A ☒ ☐ Check the appropriate box: ☐ ☐ ☒ ☐ ☐ Biostar Pharmaceuticals, Inc. _____________________________________ Payment of Filing Fee (Check the appropriate box): ☒ ☐ (1) Title of each class of securities to which transaction applies: _____________________________ (2) Aggregate number of s]
[FORM 10-K (Mark One) ☒ December 31, 2016 For the fiscal year ended: Or ☐ For the transition period from ______________ to _______________ 001-34708 BIOSTAR PHARMACEUTICALS, INC. Maryland 20-8747899 (State or other jurisdiction of incorporation of origination) (I.R.S. Employer Identification Number) ]
